**Core tip:** Pancreatic fluid collections (PFC) are a recognized complication of pancreatitis, trauma or surgical injury to the pancreas. Over the years, management has included surgical, radiologic or endoscopic intervention. Endoscopic interventions are now at the forefront for management of PFCs, and development of lumen apposing metal stents (LAMS) have made endoscopic drainage more accessible and easy. It is important for practitioners to understand the risks of LAMS including bleeding, stent migration, buried stent, stent occlusion, and perforation, as well as proper management approaches to these complications.

INTRODUCTION
============

Acute pancreatitis (AP) leads to 275000 admissions annually and \$2.5 billion in healthcare costs worldwide\[[@B1]\]. Pancreatic fluid collections (PFCs) are a burdensome, sometimes devastating complication of AP. PFCs can arise after interstitial or necrotizing pancreatitis. Acute peripancreatic fluid collections occur commonly in interstitial AP, generally resolve, and require no intervention. When an acute PFC does not resolve, a wall forms around the collection, signaling the evolution into a pancreatic pseudocyst. Pseudocysts require intervention only if they are symptomatic. Necrotizing pancreatitis that fails to resolve spontaneously can develop into walled-off necrosis (WON). As with pseudocysts, WON warrants intervention only when symptomatic or if there is clear evidence of infection\[[@B2]\]. Infected pancreatic necrosis, which may occur before or after a collection becomes walled-off, carries a mortality rate of 30%, compared to only 2% of all AP and 10% of patients with sterile necrosis\[[@B1]\].

Historically, PFCs were drained or debrided surgically or percutaneously; however, these techniques have a high risk of complications and morbidity. Endoscopic cystgastrostomy and necrosectomy have emerged as an alternative to these approaches in many cases. An endoscopic approach requires close contact between the GI lumen and PFC and is not an appropriate alternative for surgical indications other than drainage, such as bleeding or perforation\[[@B3]\]. For pseudocysts, endoscopic cystgastrostomy has been demonstrated to be as effective as surgical cystgastrostomy when it is technically feasible, but with shorter hospital stays, lower costs and higher patient physical and mental health scores\[[@B4]\]. A 2016 Cochrane review of randomized control trial data for management of pancreatic pseudocysts concluded that endoscopic ultrasound (EUS)-guided drainage leads to better short term healthcare quality of life and lower costs compared to surgical drainage\[[@B5]\]. For necrotic collections, the rate of surgical complication is as high as 72%\[[@B6],[@B7]\]. When it can be utilized, endoscopic necrosectomy has been shown to result in lower rates of major complications and death\[[@B3]\]. While there is strong data now supporting lower morbidity/mortality for endoscopic approaches over surgical approaches in PFCs, there is limited data comparing percutaneous approaches and endoscopic approaches. The main limitations of percutaneous approaches are: (1) the need for external drainage catheters; (2) the potential development of a drain tract/fistula; and (3) diameter limitations of external drainage catheters which can limit their effectiveness for WON.

Early techniques for endoscopic management of PFCs involved radiologic and endoscopic identification of an area of extrinsic gastric or duodenal compression, creation of a cystgastrostomy with a needle-knife sphincterotome, wire passage, and use of a Seldinger technique to balloon dilate the tract and place double pigtail plastic stents to maintain its patency and allow drainage\[[@B8]\]. Over the ensuing years, techniques and technologies have evolved. Endoscopic ultrasound guidance is now almost universally used for confirmation of PFC location and identification of an avascular path for drainage\[[@B5]\]. While plastic stents continue to be used commonly for simple pseudocysts, self-expanding metal biliary and esophageal stents have also been used for PFC drainage, as these have the advantage of a larger lumen, which is particularly useful in the setting of WON and in some cases to enable endoscopic necrosectomy\[[@B9]\]. Traditional self-expanding metal stents (SEMS) are designed to anchor in place in a stricture; however, when used for PFC management, there is a significant migration risk, as the size and shape of available biliary and esophageal SEMS are not specifically designed for management of pancreatic collections\[[@B10]\].

The first clinical experiences with LAMS were described in 2012, and over the last several years LAMS have been increasingly preferred by many endoscopists for cystgastrostomy and pancreatic necrosectomy procedures\[[@B11],[@B12]\]. LAMS address the need for a larger lumen for drainage and endoscopist entry into the cyst cavity, and are designed with a "dumbbell" shape with flanged ends to oppose the gastrointestinal and cyst lumens in order to reduce stent migration\[[@B11]\]. There are numerous studies showing safety and efficacy of LAMS\[[@B10]-[@B15]\]. There is also data showing the superiority of LAMS to double pigtail stents (DPS) for drainage of WON\[[@B16]\].

In early studies of both WON and pseudocysts, the use of LAMS has been associated with higher rates of clinical success, fewer required endoscopic sessions, shorter procedure times, shorter hospital stays and lower costs compared to DPS\[[@B16]-[@B20]\]. In the United States, the Axios stent (Boston Scientific) is used most commonly, but internationally, other LAMS stent designs including the Spaxus stent (TaeWoong Medical) and Nagi stent (TaeWoong Medical) are available, among others\[[@B21]\].

COMPLICATIONS OF LAMS
=====================

While much has been written regarding the technical advantages of LAMS, there has been more limited discussion of their complications. Reported complication rates vary widely. Several studies report complication rates under 10%\[[@B22]-[@B24]\]. Conversely, one group recently published their experience of conducting an interim audit during a randomized controlled trial and ultimately changing their study protocol and clinical practice due to a higher than expected complication rate of 50% in the LAMS arm of their trial\[[@B25]\]. The variations may be at least partially attributable to different definitions of complications in the studies. Given that these series represent the experiences of earlier adopters of the technology who are therapeutic endoscopists at high volume centers, broader use of these devices may either decrease complication rates, as technical experience and approaches evolve, or may increase complication rates, as these procedures become more commonly performed in centers with less clinical experience and expertise. The most common complications encountered in PFC drainage with LAMS include bleeding, stent migration/dislodgement, buried stents, stent occlusion, and perforation (Table [1](#T1){ref-type="table"}). While these complications are not unique to LAMS placement, the prevalence and management of these complications is somewhat different than for prior endoscopic drainage techniques.

###### 

Complication rates in lumen apposing metal stents case series

  **Author**                                                 **Year**   **Single/multi-center**   ***n***   **PFC type**                                  **Bleeding**   **Perforation**   **Migration**   **Buried stent**   **Failure to deploy**
  ---------------------------------------------------------- ---------- ------------------------- --------- --------------------------------------------- -------------- ----------------- --------------- ------------------ -----------------------
  Itoi et al\[[@B11]\]                                       2012       Single                    15        6 WON, 9 PC[2](#T1FN2){ref-type="table-fn"}   0%             0%                7%              0%                 0%
  Yamamoto et al\[[@B12]\]                                   2013       Multi                     9         4 WON, 5 PC                                   11%            0%                11%             0%                 0%
  Chandran et al\[[@B14]\]                                   2015       Multi                     54        9 WON, 39 PC                                  6%             0%                19%             6%                 2%
  Shah et al\[[@B10]\]                                       2015       Multi                     33        11 WON, 18 PC                                 0%             0%                3%              0%                 9%
  Walter et al\[[@B39]\]                                     2015       Multi                     61        46 WON, 15 PC                                 0%             2%                10%             0%                 2%
  Rinninella et al\[[@B24]\]                                 2015       Multi                     93        4 APFC, 37 PC, 52 WON                         1%             2%                1%              0%                 1%
  Mukai et al\[[@B40]\]                                      2015       Single                    21        19 WON, 2 PC                                  10%            0%                19%             0%                 0%
  [1](#T1FN1){ref-type="table-fn"}Mukai et al\[[@B17]\]      2015       Single                    43        WON                                           0%             2%                5%              0%                 0%
  [1](#T1FN1){ref-type="table-fn"}Siddiqui et al\[[@B19]\]   2016       Multi                     86        WON                                           7%             3%                0%              3%                 2%
  [1](#T1FN1){ref-type="table-fn"}Bang et al\[[@B25]\]       2016       Single                    12        WON                                           25%            0%                0%              17%                \-
  [1](#T1FN1){ref-type="table-fn"}Lang et al\[[@B26]\]       2016       Single                    19        9 WON 10 PC                                   21%            0%                0%              0%                 \-
  [1](#T1FN1){ref-type="table-fn"}Bapaye et al\[[@B18]\]     2017       Single                    72        WON                                           3%             0%                3%              0%                 0%
  [1](#T1FN1){ref-type="table-fn"}Ang et al\[[@B16]\]        2017       Multi                     12        8 WON, 8 PC[3](#T1FN3){ref-type="table-fn"}   0%             0%                8%              0%                 \-
  Lakhtakia et al\[[@B37]\]                                  2017       Single                    205       WON                                           3%             1%                1%              1%                 1%

Study includes multiple stent types, only LAMS cases are included here;

PFC type not explicitly defined, inferred based on description of cyst contents;

Study includes patients with multiple stent types. Number of subjects is not equal to sum of PFC types. LAMS: Lumen-apposing metal stents; WON: Walled off necrosis; PC: Pseudocyst; APFC: Acute pancreatic fluid collection.

Bleeding
--------

Cystgastrostomy, and indeed any transenteric procedure, carries a risk of hemorrhage. This can include acute bleeding, at the time of initial access and tract creation, and delayed bleeding, which can occur due to a variety of mechanisms, weeks or months after the initial procedure\[[@B25]\]. A major advantage of EUS guidance is that Doppler ultrasound helps identify an avascular path, which should reduce procedural bleeding risk. Acute bleeding or oozing at the site of mucosal entry can still occur, and can often be managed by tissue tamponade from either balloon dilation or stent placement and radial expansion. The more serious bleeding complication of endoscopic cystgastrostomy and endoscopic necrosectomy is bleeding within the PFC. The reported rate of bleeding can be as high as 25%, but is lower in most studies (Table [1](#T1){ref-type="table"}). Acute or delayed bleeding within the PFC is often not endoscopically manageable, in part due to limited visualization. Rapid bleeding, whether acute or delayed, may require immediate referral to angiographic embolization or surgery (Figure [1](#F1){ref-type="fig"}). Pseudoaneurysm development and variceal formation are expected complications in patients with severe pancreatitis and may increase the risk of bleeding during PFC management (Figure [2](#F2){ref-type="fig"}).

![Delayed bleeding after lumen apposing metal stent placement, which required angiographic embolization.](WJGE-9-456-g001){#F1}

![Pulsatile pseudoaneurysm seen on left of screen after endoscopic entry into cyst cavity, several weeks after initial lumen apposing metal stent placement for walled off necrosis.](WJGE-9-456-g002){#F2}

A comparison of LAMS and DPS in PFC drainage found that while the two treatment groups had similar rates of PFC resolution at 6 mo, there were significantly higher rates of bleeding (19% *vs* 1%, *P* = 0.0003) in the LAMS group compared to the DPS group. The bleeding events in the LAMS group included a splenic artery pseudoaneurysm, 2 collateral vessel bleeds, and an intracavitary variceal bleed; whereas the single bleeding event in the DPS group was an erosion of the stent into the gastric wall\[[@B26]\].

In a second trial comparing LAMS to DPS for management of WON, three major bleeding events requiring transfusion and ICU admission among the first 12 patients randomized to the LAMS arm were reported. All three events occurred in a delayed fashion, at 3 wk (*n =* 1) and 5 wk (*n =* 2) from LAMS placement. As a result of this experience, the authors changed their study protocol and clinical practice and now perform a CT scan 3 wk after LAMS placement to assess for PFC resolution, rather than 6 wk as is their practice for DPS and their original study protocol\[[@B25]\]. Similarly, another comparison between LAMS and DPS in WON describes erosion of the LAMS into the splenic artery as the cause of 2 bleeding complications, both of which were delayed (Table [1](#T1){ref-type="table"})\[[@B18]\].

The primary concept that has been proposed to explain the increased bleeding risk reported in the early LAMS literature is that the more rapid collapse of the collection which may occur due to the large diameter of LAMS, may lead to direct impingement of the stent on blood vessels on the cyst wall, leading to risk of pseudoaneurysm and hemorrhage. Furthermore, plastic stents are softer and more flexible, and may be less likely to cause bleeding if they encounter a vascular structure. The data regarding bleeding risk should become clearer as a larger experience develops with LAMS use. Based on the available evidence, our approach is to perform short term CT imaging after LAMS placement, typically within 3-4 wk, with the plan to endoscopically remove the stent after cyst collapse is demonstrated. In recurrent pseudocysts for which long-term drainage is desired, use of plastic stents may be preferable based on our current understanding. We also strongly recommend that physicians considering LAMS placement should have experienced angiography and surgical teams available to help manage bleeding when it occurs. This is in keeping with recommended approaches for all patients with pancreatic fluid collections, which should typically involve multidisciplinary care involving a gastroenterologist, surgeon, and radiologist.

Migration
---------

While the LAMS flanged ends are intended to anchor the stent in place, there remains some risk of stent migration after placement. Migration rates of up to 19% have been reported (Table [1](#T1){ref-type="table"}). Migration can occur either into the cyst cavity, or back into the gut lumen. Migration can occur immediately due to improper deployment of the stent, but may also occur spontaneously, weeks after stent placement, and also due to subsequent manipulation of the stent during endoscopic debridement procedures\[[@B27]\]. While some endoscopists prefer to place a double pigtail stent through the LAMS to "stabilize" the LAMS, it is currently unknown whether this approach may reduce the risk of LAMS migration, and we do not currently recommend this practice.

In the case of migration into the gastric lumen, the stent may either remain in the stomach (Figure [3](#F3){ref-type="fig"}), or pass spontaneously. Small bowel obstruction has been reported in association with LAMS migration, requiring surgical exploration for stent retrieval\[[@B28]\]. Migration of the stent into the cyst cavity can be more problematic as the cystgastrostomy tract may partially or completely close.

![Endoscopic removal of lumen apposing metal stent that migrated into gastric lumen.](WJGE-9-456-g003){#F3}

If stent migration is recognized during routine imaging or endoscopy, endoscopic removal of the stent should be pursued urgently. In the case of migration into the lumen, retrieval is straightforward if the stent is in the stomach or proximal small bowel. More distal migration of the stent may be managed with a deep enteroscopy attempt at removal, or conservatively with serial abdominal X-rays to confirm passage, and prompt surgical management if bowel obstruction occurs. Migration of the stent into the cyst cavity requires re-establishing the cyst gastrostomy tract with wire passage, dilation, and subsequent re-introduction of the endoscope into the cavity for stent retrieval using a snare or forceps. If stent retrieval is not possible endoscopically, then surgical removal is indicated.

Buried stent
------------

The term "buried stent" refers to the situation when gastric or enteric mucosa grows over the flanged end of the LAMS. This complication may occur with LAMS due to the tight apposition of the gastric and PFC lumen and the relatively low stent profile. Buried stent has been reported in up to 17% of cases in reported series (Table [1](#T1){ref-type="table"}). The management of this issue has been described in several case reports\[[@B29]-[@B31]\].

Given that buried stent is a relatively uncommon occurrence, the specific risk factors for this event are not clear. Some have proposed that placing the stent across the gastric antrum (rather than the gastric body), may increase the risk of buried stent because of the significant motility of the gastric antrum\[[@B32]\].

Techniques for removing buried stents have included the use of a needle knife device and argon plasma coagulation to partially uncover the enteric side of stent, prior to removal with a snare or forceps. Dilation of the stent and tract may also facilitate removal. When adequate exposure of the buried enteric side of the stent is not feasible, an alternative approach is to dilate the stent, enter the cavity with the endoscope through the stent, and subsequently capture the internal flange of the stent in order to facilitate removal\[[@B31]\]. Aggressive attempts at removal of a buried stent may increase the risk of bleeding, and potentially separation of the cyst cavity from the enteric wall.

Perforation
-----------

The risk of perforation when performing an upper GI endoscopy including EUS is low, at less than 0.05%\[[@B33]\]. The reported risk of perforation in endoscopic drainage of PFCs is less than 5% (Table [1](#T1){ref-type="table"})\[[@B34]\]. Peritonitis or pneumoperitoneum caused by gastric perforation or separation of the cyst wall and stomach are perhaps the most feared complications of endoscopic cystgastrostomy and similar techniques. These challenges are not specific to the use of LAMS and can occur in any endoscopic PFC drainage procedures.

While LAMS are designed to make endoscopic access into PFCs easier, and potentially safer, initial data does not suggest that LAMS use eliminates the risk of perforation. In one study comparing DPS, SEMS and LAMS, 3 cases of perforation were reported in the LAMS group (*n =* 86), all resulting from stent maldeployment. One was fixed endoscopically with an "over the scope" clip (OTSC) and two required surgical repair. In the DPS and SEMS groups (*n =* 227), there were only 2 such perforations\[[@B19]\].

Patients in whom a perforation is not immediately recognized and closed endoscopically may present immediately post procedure with abdominal/chest pain, hemodynamic instability or in a more delayed fashion with worsening clinical status including sepsis. Because patients recovering from severe pancreatitis may have pre-procedural abdominal pain, and, in some situations, features of systemic inflammatory response syndrome, post-procedural perforation may not be immediately obvious. Physicians must be alert to the risk of perforation, and initiate clinical investigation early if there is evidence of clinical deterioration or increased abdominal pain after LAMS placement. Initial management includes imaging studies such as a CT scan with contrast to assess extent. Conservative, nonsurgical management with nothing by mouth, nasogastric/nasoduodenal tube placement and intravenous antibiotics can be considered in clinically stable patients. A small perforation/leak after successful stent placement may lead to fluid or air in the peritoneum, and can potentially be followed conservatively. However, the surgical team should be consulted at time of presentation to evaluate the role of surgical intervention.

When a perforation is recognized, the endoscopist should describe the size and location of the perforation in clear terms. Endoscopic treatment of the perforation can include endoscopic clip placement, OTSC placement, endoscopic suturing, or a combination of these tools (Figure [4](#F4){ref-type="fig"})\[[@B35]\]. For gastric perforations less than 1cm, monotherapy with these tools should be considered; however, for gastric perforations of 1-3 cm, a combination of techniques may be required\[[@B35]\]. If it is clear that the stent has been deployed outside of the PFC, either from incorrect deployment or separation of the cavities, the stent should be removed and the site closed endoscopically with standard clips, OTSC, or endoscopic suturing.

![Closure of a perforation in the stomach after lumen apposing metal stents maldeployment and removal (a second gastric location was subsequently chosen for successful lumen apposing metal stents placement).](WJGE-9-456-g004){#F4}

For PFCs, perforation/pneumoperitoneum risk can be minimized by choosing a site with clear wall apposition (with ideally less than 1cm of distance) between the gut lumen and cyst wall on EUS. Carbon dioxide is also strongly preferred for all LAMS placements as this may lower the risk of tension-pneumothorax, pneumomediastinum, pneumopericardium, or abdominal compartment syndrome\[[@B35]\].

Stent occlusion
---------------

LAMS placement is intended to allow fluid and debris to flow out of the cyst cavity, and also to permit digestive juices to flow in, which may facilitate clearance of the cavity. When the stent lumen becomes occluded, either with food debris (Figure [5](#F5){ref-type="fig"}), or with cyst contents (Figure [6](#F6){ref-type="fig"}), drainage is impaired\[[@B36]\]. The prevalence of stent occlusion has not been clearly reported in the available literature, as this has not been included in the described list of complications in most available reports. While some physicians advocate placing double pigtail plastic stents through the LAMS at the time of initial placement in order to reduce the likelihood of stent occlusion, the benefit of this approach, if any, has not been evaluated in clinical trials.

![Food debris occluding lumen apposing metal stent lumen.](WJGE-9-456-g005){#F5}

![Necrotic debris occluding lumen apposing metal stent lumen.](WJGE-9-456-g006){#F6}

LAMS occlusion is important to recognize as it may slow the rate of cyst resolution, and lead to early "closure" of a partially drained cyst may also increase the risk of infection. Stent occlusion should be considered in patients who have a sudden clinical worsening (for instance new abdominal pain or fever), after initial improvement or stability following LAMS placement, and also in patients where follow-up clinical imaging demonstrates lack of improvement in cyst cavity size. Management of stent occlusion is generally straightforward, endoscopically, requiring standard techniques of debris removal, with a forceps or retrieval net, in order to re-establish the stent lumen.

An active, step-up approach to managing WON has been proposed, which employs early assessment for stent occlusion and clearing stent debris as a first re-intervention step for cases that do not resolve after LAMS placement\[[@B37]\]. If resolution still does not occur, the algorithm employs nasocystic tube with hydrogen peroxide and saline lavage, and, ultimately direct endoscopic necrosectomy for the most persistent cases.

CONCLUSION
==========

LAMS technology is a welcome and important addition to the armamentarium of gastrointestinal endoscopists managing PFCs. While these devices represent an important leap forward with regard to ease of rapid endoscopic drainage, promoting lumen apposition and limiting stent migration compared to off-label use of other stent designs, LAMS do not eliminate the risk of complications of endoscopic cystgastrostomy and endoscopic necrosectomy and may even carry some of their own unique risks. The continued study of these devices as they become more commonly used will be critical to more precisely characterize their risks and the best techniques to avoid them.

Specific questions which will be important to address in future research will include: (1) what is the appropriate/safe duration between LAMS placement and removal? (2) what are the ideal intervals of radiologic and endoscopic follow-up to reduce the risk of stent migration and buried stent? and (3) does the use of double pigtail stents placed through a LAMS have any effect on the risk migration, occlusion, or other complications? The consistent application of deliberately developed and refined protocols should help drive down the rate of LAMS complications, and will allow for safer application of these important devices as their clinical usage broadens over time\[[@B38]\].
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